David Spigel, MD, director, Lung Cancer Research Program, Sarah Cannon Research Institute, provides an update on research into MPDL3280A for the treatment of patients with lung cancer.
David Spigel, MD, director, Lung Cancer Research Program, Sarah Cannon Research Institute, provides an update on research into MPDL3280A for the treatment of patients with lung cancer.
<<<
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More